The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Mumbai event on June 24–25 will spotlight real-world impact of pharmacovigilance beyond AI adoption
Expands manufacturing push & locks in major growth deals
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
Digital platform records over 1.34 crore beneficiary registrations with QR-enabled MCH cards and real-time monitoring features
NEJM study shows strong protection across strains
Complex tumour removed in a young patient without major pancreatic loss, reducing risk of lifelong diabetes
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Doctors highlight rising respiratory risks linked to pollution, seasonal changes, and poor treatment adherence amid increasing asthma burden in India
Subscribe To Our Newsletter & Stay Updated
